Quibim, a health tech startup designing AI tools to unlock clinical imaging data, received US Food and Drug Administration authorization for its QP-Prostate computer-aided detection (CAD) solution for the detection of prostate cancer lesions on MRI scans on 19 March.
“Integrating AI technology into prostate MRI enhances diagnostic precision in identifying clinically significant prostate cancer,” said Angel Alberich-Bayarri, CEO and founder of Quibim.